Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.51 |
| ▸ | PPARG | P37231 | 7/20 | 0.51 |
| ▸ | PPARD | Q03181 | 9/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | GCG | P01275 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969639 | 0.91 | PPARD (0.58) | PPARAPPARGPPARDFFAR1FFAR4 | |
| SCHEMBL4178494 | 0.83 | PPARA (0.51) | PPARAPPARGPPARDFFAR1FFAR4 | |
| SCHEMBL3964759 | 0.80 | PPARA (0.57) | PPARAPPARGPPARDMAOB | |
| SCHEMBL3919237 | 0.79 | PPARD (0.60) | PPARAPPARGPPARDFFAR1FFAR4 | |
| SCHEMBL3964883 | 0.78 | PPARD (0.42) | PPARAPPARGPPARDFFAR1MAOB | |
| SCHEMBL3929635 | 0.78 | PPARD (0.60) | PPARAPPARGPPARDFFAR1FFAR4 | |
| SCHEMBL3963373 | 0.77 | PPARD (0.70) | PPARAPPARGPPARD | |
| SCHEMBL3968451 | 0.77 | PPARD (0.56) | PPARAPPARGPPARD | |
| SCHEMBL3964384 | 0.77 | PPARD (0.43) | PPARAPPARGPPARDFFAR1FFAR4 | |
| SCHEMBL13791565 | 0.76 | PPARG (0.47) | PPARAPPARGPPARDGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | claimed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | claimed |
| EP-1706386-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | claimed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | claimed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544707-B2 | Bicyclic derivatives as PPAR modulators | ELI LILLY AND COMPANY (US) | 2009-06-09 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| EP-1706386-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-10-04 | — | — | EP | disclosed |
| WO-2005066136-A1 | BICYCLIC DERIVATIVES AS PPAR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070106081-A1 | Bicyclic derivatives as ppar modulators | PPARD, PPARA, PPARG | PPARA 2/4885PPARG 3/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.